- Pear delivered well for the FY despite only being a post-revenue company for part of it.
- Covered lives are developing fast, and prescription numbers have just started to ramp.
- 2022 will be a full year of performance, and the company is guiding to sharp increases in prescriptions.
- Fulfillment metrics look good, meaning that on the patient side things look good, so it's all about pushing with physicians now.
- Pear is too young to make precise estimates, but based on management statements, cash burn shouldn't deplete cash reserves till mid-2023 by which time we hope to see scaling.
For further details see:
Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets